About Max
This author has not written his bio yet.
But we are proud to say that Max contributed 625 entries already.
Entries by Max
Newsletter 37/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week too, despite my commitments, I found something interesting for you. Science is moving fast! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it […]
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Newsletter 12/2026 March 22, 2026
- JMKX007129: A Next‑Generation AR‑NTD Inhibitor for Overcoming Resistance in mCRPC March 20, 2026
- AUTOTAC Degraders ATB‑238 and ATB‑239 Target AR and AR‑v7 in Advanced Prostate Cancer March 20, 2026
- ²²⁵Ac‑RAX104: A Next‑Generation PSMA Alpha Radioligand for Advanced Prostate Cancer March 20, 2026
